Track Conduit Pharmaceuticals Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Conduit Pharmaceuticals Inc. Common Stock CDT Open Conduit Pharmaceuticals Inc. Common Stock in new tab

3.95 USD
EPS
-455.91
P/B
0.11
Beta
1.81
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateApril 3, 2026
EPS-455.91
Book Value83.78
Price to Book0.11
Debt/Equity43.83
% Insiders39.936%

DCF Valuation

Tweak assumptions to recompute fair value for Conduit Pharmaceuticals Inc. Common Stock (CDT)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Conduit Pharmaceuticals Inc. Common Stock Logo Conduit Pharmaceuticals Inc. Common Stock Analysis (CDT)

United States Health Care Official Website Stock

Is Conduit Pharmaceuticals Inc. Common Stock a good investment? Conduit Pharmaceuticals Inc. Common Stock (CDT) is currently trading at 3.95 USD.

Earnings Schedule: Conduit Pharmaceuticals Inc. Common Stock is expected to release its next earnings report on April 3, 2026.

Investor FAQ

Does Conduit Pharmaceuticals Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Conduit Pharmaceuticals Inc. Common Stock?

Conduit Pharmaceuticals Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be April 3, 2026. The company currently has a trailing EPS of -455.91.

Company Profile

CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

Exchange Ticker
NMS (United States) CDT

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Jan. 27, 2025 0.010000
May 20, 2025 0.070000
Oct. 13, 2025 0.120000
May 20, 2025 0.070000
March 27, 2026 0.040000
May 20, 2025 0.070000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion